Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Jan 03, 2012 Nature speaks with Keim about H5N1 studies -
-
-
Jun 20, 2011 Promising skin-cancer drug nears approval
Share on Twitter
Share on Facebook
Email to a friend
Print Article
Cancer Center studies lead to new trials for malignant melanoma treatment
[Source: Sara Hammond, Arizona Cancer Center] - Research at the Arizona Cancer Center has resulted in the opening of a Phase 3 clinical trial for the treatment of metastatic malignant melanoma using an approved breast-cancer drug.
The center has been studying the drug nab-paclitaxel, trade named Abraxane, for seven years.
The therapy was developed by biotechnology company Abraxis BioScience, which is conducting a worldwide, multicenter, multinational Phase 3 trial of Abraxane in metastatic melanoma, with Arizona Cancer Center physician scientist Dr. Evan Hersh as the principal investigator.
For more informaiton: Cancer Center Studies Lead to New Trials for Malignant Melanoma Treatment
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
